Top Page
Innovative Pharmaceutical Biotech
(0399)
Innovative Pharmaceutical Biotech (0399) vs. iShares MSCI Hong Kong ETF (EWH)
Innovative Pharmaceutical Biotech Business Overview & Revenue Model
Innovative Pharmaceutical Biotech Financial Statement Overview
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.46M | 6.59M | 8.07M | 11.14M | 15.19M | 14.58M |
| Gross Profit | -666.00K | 840.00K | 858.00K | 1.05M | 1.41M | 1.62M |
| EBITDA | -7.13M | 317.75M | -18.82M | -22.30M | -18.81M | -80.49M |
| Net Income | 11.46M | 103.40M | -245.70M | 296.54M | -395.75M | -407.56M |
Balance Sheet | ||||||
| Total Assets | 1.38B | 1.38B | 1.38B | 1.39B | 1.40B | 1.42B |
| Cash, Cash Equivalents and Short-Term Investments | 428.00K | 3.08M | 1.33M | 4.08M | 8.99M | 22.94M |
| Total Debt | 895.34M | 1.01B | 1.19B | 941.84M | 991.48M | 789.85M |
| Total Liabilities | 907.62M | 1.06B | 1.24B | 999.73M | 1.04B | 851.11M |
| Stockholders Equity | -458.92M | -611.51M | -795.07M | -549.37M | -595.35M | -390.37M |
Cash Flow | ||||||
| Free Cash Flow | -6.53M | -8.28M | -17.64M | -12.34M | -25.01M | -36.22M |
| Operating Cash Flow | -6.53M | -8.28M | -17.64M | -12.34M | -25.01M | -36.22M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -1.00K | 13.00K | 49.98M |
| Financing Cash Flow | 6.45M | 10.32M | 14.92M | 7.30M | 10.57M | -9.48M |
Innovative Pharmaceutical Biotech Technical Analysis
Innovative Pharmaceutical Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $1.04T | 7.17 | 7.04% | 11.71% | 37.04% | ||
76 Outperform | $93.72B | 20.39 | 13.20% | 2.45% | -9.60% | -27.18% | |
69 Neutral | HK$100.15B | 52.78 | 6.14% | 1.43% | 7.63% | -24.23% | |
65 Neutral | HK$68.42B | 15.19 | 6.22% | 1.76% | -2.82% | 11.93% | |
62 Neutral | €32.67B | 8.99 | 6.98% | ― | ― | ||
56 Neutral | HK$7.90B | 6.73 | -0.67% | 10.14% | 0.07% | -13.06% | |
44 Neutral | HK$420.83M | 36.19 | ― | -23.08% | -85.52% |
Innovative Pharmaceutical Biotech Corporate Events
Innovative Pharmaceutical Biotech Limited has announced its strategic move into the blockchain technology sector, aiming to enhance transparency, security, and efficiency in digital and commercial transactions. This initiative is part of the company’s efforts to diversify its revenue streams and strengthen its competitive position in emerging sectors, aligning with global digital transformation trends. The company plans to establish a dedicated technology team and leverage partnerships with leading blockchain platforms and academic institutions to spearhead research and development. Despite market uncertainties, the company remains optimistic about its prospects and is exploring new business opportunities to enhance performance.
Innovative Pharmaceutical Biotech Limited has announced the appointment of three new directors, effective April 11, 2025. Mr. Zhang Shen will join as an executive director, bringing his expertise in blockchain technology and asset management, while Mr. Zhang Yi will serve as a non-executive director, leveraging his experience in software development and blockchain technologies. Additionally, Ms. Sun Sizheng has been appointed as an independent non-executive director. These appointments are expected to strengthen the company’s leadership team and enhance its strategic direction in the biotechnology sector.
Innovative Pharmaceutical Biotech Limited has announced the composition of its board of directors and the establishment of three key committees: audit, remuneration, and nomination. This organizational structure is likely to enhance the company’s governance and operational efficiency, potentially strengthening its position in the pharmaceutical and biotech markets.
Innovative Pharmaceutical Biotech Limited announced significant changes in its board of directors effective April 7, 2025. The company has accepted the resignations of Mr. Li Jiehong as executive director and Ms. Jiang Nian as non-executive director, both stepping down to focus on personal business engagements. The board expressed gratitude for their contributions. In their place, Dr. Long Fan and Dr. Wu Ming have been appointed as executive directors, while Dr. Xia Tingkang, Tim, joins as an independent non-executive director. Additionally, Mr. Tang Rong has been appointed to the remuneration committee. These changes are expected to bring fresh perspectives and expertise to the company’s leadership, potentially impacting its strategic direction and stakeholder relations.
Innovative Pharmaceutical Biotech Limited has announced the composition of its board of directors, which includes both executive and independent non-executive members. The board has also established three committees: audit, remuneration, and nomination, with specific directors assigned to each committee. This announcement reflects the company’s commitment to maintaining a structured governance framework, which could enhance its operational efficiency and transparency, potentially impacting its market positioning positively.
Innovative Pharmaceutical Biotech Limited announced that during its Special General Meeting held on March 28, 2025, shareholders approved the appointment of SFAI (HK) CPA Limited as the company’s auditor. The resolution was passed unanimously, with all votes cast in favor. This decision is expected to enhance the company’s financial oversight and transparency, potentially strengthening its market position and stakeholder confidence.
Innovative Pharmaceutical Biotech Limited announced significant changes in its leadership structure, effective March 25, 2025. Ms. Jiang Nian has resigned as Chairman and chairman of the Nomination Committee, while Dr. Yeung Yung has been appointed to these roles. Dr. Yeung brings extensive experience from the automotive and finance sectors, which may influence the company’s strategic direction. This leadership transition could impact the company’s operations and market positioning, potentially affecting stakeholders’ interests.
Innovative Pharmaceutical Biotech Limited, a company incorporated in the Cayman Islands and continued in Bermuda, has announced the composition of its board of directors and the establishment of three key committees: audit, remuneration, and nomination. The announcement outlines the roles and functions of each board member, highlighting the company’s governance structure and commitment to oversight and strategic management.
Innovative Pharmaceutical Biotech Limited announced that its subsidiary, Fosse Bio-Engineering Development Limited, has entered into an agency agreement with Terry Bio Pharmaceutical Co., Ltd. This agreement appoints Terry Bio Pharmaceutical as the exclusive agent to market, distribute, sell, and promote Fosse Bio-Engineering’s oral pancreatic health products in Thailand for a period of six years, with an automatic renewal for another six years. This strategic move aims to expand the company’s market presence in Thailand, contingent on obtaining necessary approvals by May 2025.
Innovative Pharmaceutical Biotech Limited has issued a clarification announcement regarding a clerical error in the notice for its upcoming special general meeting (SGM) on March 28, 2025. The company clarified that there will be no closure of the register of members for the SGM, and all other information in the original notice remains unchanged. This announcement ensures that stakeholders are correctly informed about the procedures for attending and voting at the SGM, maintaining transparency and accuracy in its communications.
Innovative Pharmaceutical Biotech Limited has announced a special general meeting to be held on March 28, 2025, to appoint SFAI (HK) CPA Limited as the company’s auditor. This move is expected to streamline the company’s financial auditing processes, potentially enhancing its operational efficiency and transparency, which could positively impact its market positioning and stakeholder confidence.
Innovative Pharmaceutical Biotech Limited, a company incorporated in the Cayman Islands and continued in Bermuda, has announced the composition of its board of directors and the establishment of three committees: audit, remuneration, and nomination. The board includes executive, non-executive, and independent non-executive directors, with Ms. Jiang Nian serving as the Chairman. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the leadership and oversight mechanisms in place.
Innovative Pharmaceutical Biotech Limited announced the resignation of Mr. Cheng Tak Yiu as an executive director, effective March 4, 2025. Mr. Cheng resigned to focus on personal business engagements, and his departure is amicable, with no disagreements reported. The company expressed gratitude for his contributions, and this change is not expected to impact its operations or market position.
Innovative Pharmaceutical Biotech Limited has announced a significant shift in its boardroom with the resignation of Ms. Wu Yanmin and Ms. Xiao Yan from their roles as non-executive directors, effective February 11, 2025, as they pursue other personal business engagements. Concurrently, the company has bolstered its leadership by appointing Mr. Li Jiehong and Ms. Qi Shujuan as executive directors, bringing extensive experience in financial sectors and leadership roles to the company, potentially enhancing its strategic direction and operational efficiency.
Innovative Pharmaceutical Biotech Limited has announced the composition of its board of directors, comprised of executive, non-executive, and independent non-executive directors. The board oversees three committees: the audit, remuneration, and nomination committees, each with specified directors assigned to leadership and membership roles.